David Darling has a dig at DHB delays

David Darling has a dig at DHB delays
David Darling: Disappointed with slow adoption (Image: Supplied)
Brent Melville
Pacific Edge’s cancer diagnostic products have made headway into the US healthcare sector over the past several years, but many New Zealand patients continue to be shut out by the bureaucracy of local DHBs, the company says.Last June, the NZX-listed firm announced giant US healthcare group Kaiser Permanente had approved its Cxbladder products for use by urologists to monitor patients for bladder cancer. A month later it announced Cxbladder tests will be covered by the Centers for Medicare and Medicaid Services (CMS) across the US mar...

More Markets

Tower's risk-based revolution
Markets

Tower's risk-based revolution

It's one of the few insurers in Australasia growing. How?

RBNZ plan to cut AT1 capital layer wins cautious lender support
Finance

RBNZ plan to cut AT1 capital layer wins cautious lender support

Proposal to pare AT1 capital from prudential stacks wins cautious support from lenders.

NZ sharemarket starts week down 0.8%
Markets Market Close

NZ sharemarket starts week down 0.8%

The S&P/NZX 50 Index closed at 13,351.92, down 115.34 points or 0.86%.

Graham Skellern 13 Oct 2025
ANZ NZ continues to hold market-leading position: ANZ Group
Finance

ANZ NZ continues to hold market-leading position: ANZ Group

ANZ NZ holds market-leading position, continues re-platforming: ANZ Group 

Staff reporters 13 Oct 2025